The significant increase of inflammatory molecules flooding the brain during different illnesses associated with pain may contribute to the associated depressive state through a biological pathway (re-enforcing the psychological depressive status usually associated with organic diseases).
New therapeutic strategies should consider reduction of agonists and/or using drugs (“antagonists”) that can down-regulated the release of pro-inflammatory, angiogenic and neurotrophic factors from the mastcells.